| News Updates |
 |
Merck's oral HIV treatment as effective as Gilead's Biktarv
The Jerusalem Post | November 24, 2025
|
|
Systemic inflammation in suppressed HIV similar after switch to 3-drug ART
EATG | November 22, 2025
|
|
Systemic Inflammation in Suppressed HIV Similar After Switch to 3-Drug ART
IDA | November 21, 2025
|
|
Merck's oral HIV treatment meets main goal in late-stage study
Reuters | November 19, 2025
|
|
Antibody drugs show promise for treating bird flu and HIV
Nature | November 5, 2025
|
|
CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies
HIV+HEP | October 22, 2025
|
|
HIV Preventive Treatment Could Be Sold for One Thousandth of Current List Price
IDSA | October 19, 2025
|
|
Gilead to present data on potential first weekly oral treatment for HIV
Yahoo! News | October 15, 2025
|
|
Once-Weekly Oral ISL/LEN Combo for HIV Treatment Found Safe and Effective, With High Adherence
Infectious Disease Special Edition | October 17, 2025
|
|
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with...
ViiV Healthcare | October 17, 2025
|
|
Novel HIV Combo Therapy of Lenacapavir and 2 bNAbs Found Effective, Well Tolerated in in Phase 2 Trial
Infectious Disease Special Edition | October 17, 2025
|
|
Integrase inhibitors maintain efficacy despite “outside” mutations, UK study finds
European AIDS Treatment Group | October 12, 2025
|
|
'We can end HIV': Groundbreaking preventative drug to be rolled out for $40 a year from 2027
France24 | September 25, 2025
|
|
Gates Foundation partners with Indian manufacturer to drive down cost of, accelerate access to groundbreaking HIV prevention tool
Gates Foundation | September 24, 2025
|
|
UNAIDS welcomes the announcement of new deals to make new HIV prevention medicines available and affordable for people in need
UNAIDS | September 24, 2025
|
|
HIV Drug Resistance Is Declining Over Time
POZ Magazine | September 24, 2025
|
|
From Bench to Breakthrough: How Curiosity Led to an Extraordinarily Effective HIV Drug
University of Utah Health | September 22, 2025
|
|
New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis
News Medical | August 26, 2025
|
|
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
Gilead | August 26, 2025
|
|
HIV: Monthly PrEP Drug Candidate Shows Promise
Newsweek | August 26, 2025
|
|
HIV Treatment Overview
NIH | August 20, 2025
|
|
Lenacapavir will not end the HIV epidemic in the current US political climate
The Lancet | August 2025
|
|
Innovative administration of long-acting injectables for HIV treatment enhancement at home (INVITE-HOME): implementation science...
NIH | August 5, 2025
|
| |
|
